These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2468055)

  • 1. The haemodynamic profile of cromakalim in the cat.
    Clapham JC; Buckingham RE
    J Cardiovasc Pharmacol; 1988; 12(5):555-61. PubMed ID: 2468055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive and haemodynamic properties of the potassium channel activating (-) enantiomer of cromakalim in animal models.
    Clapham JC; Hamilton TC; Longman SD; Buckingham RE; Campbell CA; Ilsley GL; Gout B
    Arzneimittelforschung; 1991 Apr; 41(4):385-91. PubMed ID: 1907150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacology of Ro 31-6930, a new potassium channel opener.
    Paciorek PM; Burden DT; Burke YM; Cowlrick IS; Perkins RS; Taylor JC; Waterfall JF
    J Cardiovasc Pharmacol; 1990 Feb; 15(2):188-97. PubMed ID: 1689412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemodynamic differences between cromakalim and pinacidil: comparison with nifedipine.
    Clapham JC; Longman SD
    Eur J Pharmacol; 1989 Nov; 171(1):109-17. PubMed ID: 2693121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the haemodynamic profiles of Ro 31-6930, cromakalim and nifedipine in anaesthetised normotensive rats.
    Duty S; Paciorek PM; Waterfall JF; Weston AH
    Eur J Pharmacol; 1990 Aug; 185(1):35-42. PubMed ID: 2226633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary and systemic haemodynamic effects of cromakalim in conditions of normoxia and hypoxia in dogs.
    Martin DJ; Gellotte M; Armstrong JM; Hicks PE
    J Auton Pharmacol; 1990 Oct; 10(5):261-72. PubMed ID: 2084109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil.
    Longman SD; Clapham JC; Wilson C; Hamilton TC
    J Cardiovasc Pharmacol; 1988; 12(5):535-42. PubMed ID: 2468052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular effects of the novel potassium channel opener UR-8225.
    Tamargo J; Pérez O; Delpón E; García-Rafanell J; Gómez L; Cavalcanti F
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):295-305. PubMed ID: 7475055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic and cardiac effects of BMS-180448, a novel K+ATP opener, in anesthetized dogs and isolated rat hearts.
    D'Alonzo AJ; Grover GJ; Darbenzio RB; Sewter JC; Hess TA; Dzwonczyk S; Sleph PG
    Pharmacology; 1996 Feb; 52(2):101-12. PubMed ID: 8851631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models.
    Buckingham RE; Clapham JC; Hamilton TC; Longman SD; Norton J; Poyser RH
    J Cardiovasc Pharmacol; 1986; 8(4):798-804. PubMed ID: 2427821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of cromakalim (BRL 34915) in healthy volunteers.
    Fox JS; Whitehead EM; Shanks RG
    Br J Clin Pharmacol; 1991 Jul; 32(1):45-9. PubMed ID: 1888641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of KRN2391 in anesthetized dogs: a comparison with cromakalim and nitroglycerin.
    Kaneta S; Yokoyama T; Izumi H; Izawa T; Ogawa N
    Arch Int Pharmacodyn Ther; 1994; 327(2):184-93. PubMed ID: 7979827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the airways relaxant and hypotensive potencies of the potassium channel activators BRL 55834 and levcromakalim (BRL 38227) in vivo in guinea-pigs and rats.
    Bowring NE; Arch JR; Buckle DR; Taylor JF
    Br J Pharmacol; 1993 Aug; 109(4):1133-9. PubMed ID: 8401925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute haemodynamic effects of cromakalim in patients with angina pectoris.
    Thomas P; Dixon MS; Winterton SJ; Sheridan DJ
    Br J Clin Pharmacol; 1990 Mar; 29(3):325-31. PubMed ID: 2310656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of pulmonary and systemic vascular responses to cromakalim, an activator of K+ATP channels.
    Minkes RK; Kvamme P; Higuera TR; Nossaman BD; Kadowitz PJ
    Am J Physiol; 1991 Mar; 260(3 Pt 2):H957-66. PubMed ID: 1825747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of BRL 34915 (cromakalim) on renal hemodynamics and function in anesthetized dogs.
    Hayashi K; Matsumura Y; Yoshida Y; Ohyama T; Hisaki K; Suzuki Y; Morimoto S
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1240-6. PubMed ID: 2108239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of short-term administration of cromakalim on renal hemodynamics and eicosanoid excretion in essential hypertension.
    Lebel M; Grose JH; Lacourcière Y
    Am J Hypertens; 1991 Sep; 4(9):740-4. PubMed ID: 1834087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Potassium agonists: regional vasodilator profile in rats].
    Richer C; Mulder P; Doussau MP; Giudicelli JF
    Arch Mal Coeur Vaiss; 1989 Jul; 82(7):1333-7. PubMed ID: 2510669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of nifedipine, verapamil and diltiazem on pulmonary vascular resistance and vasoconstrictors in cats.
    Erdemli O; Hao Q; Cai B; Lippton HL; Hyman A
    Arch Int Pharmacodyn Ther; 1994; 328(2):165-79. PubMed ID: 7535994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of KRN2391, nitroglycerin and cromakalim in dihydroergotamine-treated pithed rats.
    Kaneta S; Kashiwabara T; Tanaka Y; Yokoyama T; Izumi H; Izawa T; Ogawa N
    Gen Pharmacol; 1994 Sep; 25(5):963-8. PubMed ID: 7835645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.